vs
CANTALOUPE, INC.（CTLP）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
Tarsus Pharmaceuticals, Inc.的季度营收约是CANTALOUPE, INC.的1.9倍（$151.7M vs $78.7M），CANTALOUPE, INC.净利率更高（-0.1% vs -5.5%，领先5.4%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 6.8%），Tarsus Pharmaceuticals, Inc.自由现金流更多（$13.0M vs $-614.0K），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 7.7%）
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
CTLP vs TARS — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $78.7M | $151.7M |
| 净利润 | $-70.0K | $-8.4M |
| 毛利率 | — | — |
| 营业利润率 | 2.0% | -5.3% |
| 净利率 | -0.1% | -5.5% |
| 营收同比 | 6.8% | 128.4% |
| 净利润同比 | -101.4% | 63.8% |
| 每股收益（稀释后） | $0.00 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $78.7M | $151.7M | ||
| Q3 25 | $80.9M | $118.7M | ||
| Q2 25 | $82.6M | $102.7M | ||
| Q1 25 | $75.4M | $78.3M | ||
| Q4 24 | $73.7M | $66.4M | ||
| Q3 24 | $70.8M | $48.1M | ||
| Q2 24 | $72.7M | $40.8M | ||
| Q1 24 | $67.9M | $27.6M |
| Q4 25 | $-70.0K | $-8.4M | ||
| Q3 25 | $-919.0K | $-12.6M | ||
| Q2 25 | $6.8M | $-20.3M | ||
| Q1 25 | $49.2M | $-25.1M | ||
| Q4 24 | $5.0M | $-23.1M | ||
| Q3 24 | $3.6M | $-23.4M | ||
| Q2 24 | $2.2M | $-33.3M | ||
| Q1 24 | $4.7M | $-35.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 39.6% | — |
| Q4 25 | 2.0% | -5.3% | ||
| Q3 25 | 2.0% | -12.2% | ||
| Q2 25 | 6.3% | -21.6% | ||
| Q1 25 | 9.1% | -33.5% | ||
| Q4 24 | 8.4% | -36.8% | ||
| Q3 24 | 5.8% | -52.3% | ||
| Q2 24 | 4.9% | -81.6% | ||
| Q1 24 | 6.3% | -136.5% |
| Q4 25 | -0.1% | -5.5% | ||
| Q3 25 | -1.1% | -10.6% | ||
| Q2 25 | 8.3% | -19.8% | ||
| Q1 25 | 65.2% | -32.1% | ||
| Q4 24 | 6.7% | -34.8% | ||
| Q3 24 | 5.0% | -48.7% | ||
| Q2 24 | 3.0% | -81.6% | ||
| Q1 24 | 6.9% | -129.4% |
| Q4 25 | $0.00 | $-0.17 | ||
| Q3 25 | $-0.02 | $-0.30 | ||
| Q2 25 | $0.10 | $-0.48 | ||
| Q1 25 | $0.65 | $-0.64 | ||
| Q4 24 | $0.07 | $-0.57 | ||
| Q3 24 | $0.04 | $-0.61 | ||
| Q2 24 | $0.03 | $-0.88 | ||
| Q1 24 | $0.06 | $-1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.0M | $417.3M |
| 总债务越低越好 | $37.7M | $72.4M |
| 股东权益账面价值 | $252.5M | $343.4M |
| 总资产 | $381.9M | $562.2M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.21× |
8季度趋势，按日历期对齐
| Q4 25 | $53.0M | $417.3M | ||
| Q3 25 | $55.0M | $401.8M | ||
| Q2 25 | $51.1M | $381.1M | ||
| Q1 25 | $46.3M | $407.9M | ||
| Q4 24 | $27.7M | $291.4M | ||
| Q3 24 | $33.1M | $317.0M | ||
| Q2 24 | $58.9M | $323.6M | ||
| Q1 24 | $50.2M | $298.5M |
| Q4 25 | $37.7M | $72.4M | ||
| Q3 25 | $38.3M | $72.3M | ||
| Q2 25 | $38.7M | $72.1M | ||
| Q1 25 | $39.2M | $72.0M | ||
| Q4 24 | $37.0M | $71.8M | ||
| Q3 24 | $37.3M | $71.7M | ||
| Q2 24 | $37.5M | $71.6M | ||
| Q1 24 | $38.1M | $29.9M |
| Q4 25 | $252.5M | $343.4M | ||
| Q3 25 | $251.8M | $335.1M | ||
| Q2 25 | $251.0M | $332.6M | ||
| Q1 25 | $240.7M | $342.5M | ||
| Q4 24 | $190.1M | $224.5M | ||
| Q3 24 | $186.2M | $237.5M | ||
| Q2 24 | $181.7M | $252.2M | ||
| Q1 24 | $178.8M | $275.2M |
| Q4 25 | $381.9M | $562.2M | ||
| Q3 25 | $389.5M | $534.6M | ||
| Q2 25 | $381.9M | $495.0M | ||
| Q1 25 | $370.5M | $500.8M | ||
| Q4 24 | $303.0M | $377.0M | ||
| Q3 24 | $312.1M | $376.3M | ||
| Q2 24 | $335.6M | $376.8M | ||
| Q1 24 | $319.9M | $349.3M |
| Q4 25 | 0.15× | 0.21× | ||
| Q3 25 | 0.15× | 0.22× | ||
| Q2 25 | 0.15× | 0.22× | ||
| Q1 25 | 0.16× | 0.21× | ||
| Q4 24 | 0.19× | 0.32× | ||
| Q3 24 | 0.20× | 0.30× | ||
| Q2 24 | 0.21× | 0.28× | ||
| Q1 24 | 0.21× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $-614.0K | $13.0M |
| 自由现金流率自由现金流/营收 | -0.8% | 8.6% |
| 资本支出强度资本支出/营收 | 4.8% | 4.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $25.8M | $-22.3M |
8季度趋势，按日历期对齐
| Q4 25 | $3.1M | $19.3M | ||
| Q3 25 | $7.0M | $18.3M | ||
| Q2 25 | $9.4M | $-29.4M | ||
| Q1 25 | $22.4M | $-20.7M | ||
| Q4 24 | $522.0K | $-22.2M | ||
| Q3 24 | $-12.0M | $-8.7M | ||
| Q2 24 | $14.3M | $-14.4M | ||
| Q1 24 | $14.7M | $-37.8M |
| Q4 25 | $-614.0K | $13.0M | ||
| Q3 25 | $3.5M | $16.3M | ||
| Q2 25 | $4.3M | $-30.4M | ||
| Q1 25 | $18.6M | $-21.2M | ||
| Q4 24 | $-3.8M | $-22.3M | ||
| Q3 24 | $-15.8M | $-8.9M | ||
| Q2 24 | $8.5M | $-15.4M | ||
| Q1 24 | $11.4M | $-38.0M |
| Q4 25 | -0.8% | 8.6% | ||
| Q3 25 | 4.4% | 13.8% | ||
| Q2 25 | 5.3% | -29.6% | ||
| Q1 25 | 24.6% | -27.1% | ||
| Q4 24 | -5.1% | -33.5% | ||
| Q3 24 | -22.3% | -18.6% | ||
| Q2 24 | 11.7% | -37.8% | ||
| Q1 24 | 16.9% | -137.5% |
| Q4 25 | 4.8% | 4.2% | ||
| Q3 25 | 4.2% | 1.6% | ||
| Q2 25 | 6.2% | 1.0% | ||
| Q1 25 | 5.1% | 0.8% | ||
| Q4 24 | 5.8% | 0.1% | ||
| Q3 24 | 5.4% | 0.6% | ||
| Q2 24 | 7.9% | 2.5% | ||
| Q1 24 | 4.8% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.38× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | -3.36× | — | ||
| Q2 24 | 6.47× | — | ||
| Q1 24 | 3.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
TARS
暂无分部数据
